Monoclonal antibodies against NKG2A
US10160810B2 · kind B2 · utility
14Cited by
7References
5Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jan 12, 2015 |
| Grant date | Dec 25, 2018 |
| Priority date | — |
| Expiry date | May 20, 2036 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2500/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to methods of treating immune disorders, particularly autoimmune or inflammatory disorders, and methods of producing antibodies and other compounds for use in therapeutic strategies for treating such disorders. Generally, the present methods involve the use of antibodies or other compounds that prevent the stimulation of NKG2A receptors on NK cells, leading to the lysis of dendritic cells that contribute to the pathology of the disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.